3XB0 Stock Overview
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Xenetic Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.22 |
| 52 Week High | US$9.22 |
| 52 Week Low | US$2.14 |
| Beta | 2.89 |
| 1 Month Change | 0% |
| 3 Month Change | -10.56% |
| 1 Year Change | -64.63% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3XB0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | 2.5% |
| 1Y | -64.6% | -21.2% | 5.4% |
Return vs Industry: 3XB0 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 3XB0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 3XB0 volatility | |
|---|---|
| 3XB0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3XB0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 3XB0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 4 | Jeff Eisenberg | www.xeneticbio.com |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.
Xenetic Biosciences, Inc. Fundamentals Summary
| 3XB0 fundamental statistics | |
|---|---|
| Market cap | €4.99m |
| Earnings (TTM) | -€5.31m |
| Revenue (TTM) | €1.76m |
2.8x
P/S Ratio-0.9x
P/E RatioIs 3XB0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3XB0 income statement (TTM) | |
|---|---|
| Revenue | US$1.92m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.92m |
| Other Expenses | US$7.74m |
| Earnings | -US$5.82m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.83 |
| Gross Margin | 100.00% |
| Net Profit Margin | -302.29% |
| Debt/Equity Ratio | 0% |
How did 3XB0 perform over the long term?
See historical performance and comparison